Publicaciones en colaboración con investigadores/as de University of Antwerp (10)

2023

  1. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

  2. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 170, pp. 300-308

2022

  1. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

    Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43

2021

  1. In response to Haas RL et al.

    Radiotherapy and Oncology

2020

  1. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer

    Radiotherapy and Oncology, Vol. 149, pp. 150-157

  2. ESTRO/ACROP IORT recommendations for intraoperative radiation therapy in primary locally advanced rectal cancer

    Clinical and Translational Radiation Oncology, Vol. 25, pp. 29-36

  3. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

2019

  1. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

2015

  1. Looking into the "Garden of the Hesperides": New drugs for hepatocellular carcinoma

    Minerva Chirurgica, Vol. 70, Núm. 2, pp. 119-129

  2. cMET in NSCLC: Can we cut off the head of the Hydra? From the pathway to the resistance

    Cancers, Vol. 7, Núm. 2, pp. 556-573